Two new probe products helped Neoprobe Corp. narrow losses and boost revenue in 2009, but the unwinding of a complex financing deal cost the company $34 million in noncash charges. Neoprobe, which ...
Neoprobe Corp. (OTCBB:NEOP) has taken a step forward in the often-lengthy regulation process to commercialize its cancer-detection drug, RIGScan. The company said it intends to file a Biologic License ...
DUBLIN, Ohio--(BUSINESS WIRE)-- Neoprobe Corporation (NYSE Amex: NEOP) announced today that it has reached an agreement with Platinum Montaur Life Sciences, LLC and its affiliate Platinum Partners ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results